Patrick Yue

机构：Phusis Therapeutics (United States) · ORCID：0009-0000-2884-9151

发表论文 81 篇 · 总被引 3836 次 · h-index 29

代表论文

• Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy (2021 · Stroke · 被引 66)
• Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor–Related Atraumatic Intracerebral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual Care (2021 · Stroke · 被引 65)
• Thirty‐day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life‐threatening direct oral anticoagulant‐related bleeding (2022 · Journal of the American College of Emergency Physicians Open · 被引 40)
• Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban (2022 · Thrombosis and Haemostasis · 被引 38)
• Restart of Anticoagulant Therapy and Risk of Thrombosis, Rebleeding, and Death after Factor Xa Inhibitor Reversal in Major Bleeding Patients (2021 · Thrombosis and Haemostasis · 被引 26)
• A phase 1 study in healthy participants to characterize the safety and pharmacology of inclacumab, a fully human anti-P-selectin antibody, in development for treatment of sickle cell disease (2023 · European Journal of Clinical Pharmacology · 被引 13)